BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated D-dimer level (cohort 1), patients with an elevated D-dimer level or an age of at least 75 years (cohort 2), and all the enroll...
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although...
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although...
Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5â7%. On Jun...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
Background: patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howe...
Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appr...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5â7%. On Jun...
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although...
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although...
Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5â7%. On Jun...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
Background: patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howe...
Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. Howev...
Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appr...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
PURPOSE: To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxi...
Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5â7%. On Jun...
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although...
Acutely ill hospitalized medical patients are at high risk of venous thromboembolism (VTE). Although...
Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5â7%. On Jun...